Aurobindo Pharma Ltd Financials
Company Logo

Aurobindo Pharma Ltd Financial Statement

Aurobindo Pharma Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2025
Revenue2845.97
Operating Expense2135.48
Net Profit408.17
Net Profit Margin14.34
Earning Per Share7.03
EBIDTA718.39
Effective Tax Rate21.85

Aurobindo Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual10,645.64
Operating Expenses Annual8,421.60
Operating Profit Annual2,894.14
Interest Annual182.60
Depreciation236.72
Net Profit Annual1,900.10
Tax Annual502.82

Aurobindo Pharma Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning357.13
Cash Flow from Operations1,714.80
Cash Flow from Investing-151.58
Cash Flow from Financing-1,837.03
Cash Flow at the End83.32

Aurobindo Pharma Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)27.19
PBIT Margin (%)24.79
PBT Margin (%)24.65
Net PROFIT Margin (%)18.36
Return On Networth / Equity (%)10.35
Return On Networth /Employed (%)11.74
Return On Assets (%)8.63
Total Debt / Equity (X)0.19
Asset Turnover Ratio (%)0.47

Aurobindo Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual2,419.13
Total Current Assets Annual7,239.13
Non Current Assets Annual17,914.85
Total Shareholders Funds Annual19,722.82
Total Assets Annual25,153.98

Aurobindo Pharma Ltd Earning Calls

EPS (INR)

Expected

15.56

Reported

15.56

Surprise

0.00%

Dec 2024

EPS beaten by 0.00%

Sep 2024

EPS beaten by 0.00%

Jun 2024

EPS beaten by -0.50%

FAQS on Aurobindo Pharma Ltd Financials

As of May 30, 2025, Aurobindo Pharma Ltd has a market capitalization of 67,951.30 Cr. Value Research classifies it as a Large-Cap company.

Yes, Aurobindo Pharma Ltd is with a debt-to-equity ratio of 0.23.

In FY 2024 , Aurobindo Pharma Ltd recorded a total revenue of approximately 10,788.09 Cr marking a significant milestone in the company's financial performance.

Aurobindo Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.4% and 0.1% annually, respectively..

Aurobindo Pharma Ltd's current PE ratio is 38.90.

Aurobindo Pharma Ltd's ROCE averaged 9.9% from the FY ending March 2023 to 2025, with a median of 10.3%. It peaked at 11.7% in March 2024, reflecting strong capital efficiency over the period..

Aurobindo Pharma Ltd's latest EBIT is Rs. 2,588.49 Cr, surpassing the average EBIT of Rs. 2,306.19 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions